Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Active, not recruiting · NCT03911973 · Registry updated 2024-06-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2024-06-07 | NCT03911973 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Celcuity Inc | 5 |
| Kari Wisinski | 2 |
| Pfizer | 431 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | United States | 38 |
| Northwestern University Feinberg School Of Medicine | Chicago | United States | 49 |
| University of Illinois Cancer Center | Chicago | United States | 34 |
| University of Iowa Hospital and Clinics | Iowa City | United States | 30 |
| University of Wisconsin | Madison | United States | 85 |